ERBB2 and neoplasm: Tumor phenotypes on baseline biopsy were distributed as follows: HR-positive/HER2-negative 23.5% (n = 105), triple-negative 35% (n = 156) and HER2-positive 41.5% (n = 185; HER2-positive/HR-positive, n = 104; HER2-positive/HR-negative, n = 81).